Hormonal Dysfunction and Male Infertility: A Comprehensive Review of Current Treatment Options

Raed AlAsmi[1]

[1] Assistant Professor of Urology , Department of Surgery, College of Medicine, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia, Email: r.alkahtani@psau.edu.sa

KEYWORDS

Fertility, Hormones, Reproductive system, Erectile dysfunction, Testosterone

ABSTRACT:

Male infertility affects millions of couples worldwide, with hormonal dysfunction significantly contributing. In recent years, significant progress has been made in understanding the complex interplay between hormonal imbalances and male infertility. This review article aims to provide a comprehensive literature overview of the current treatment options for male infertility resulting from hormonal dysfunction. The review covers the pathophysiology of hormonal imbalances and their effects on male fertility, including the role of testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and prolactin. In addition, different diagnostic techniques, such as blood tests, were also discussed. Moreover, various treatment options for hormonal imbalances, such as Hormonal replacement therapy (Selective estrogen receptor modulators**,** Aromatase inhibitors and Gonadotropin therapy), are discussed. Each treatment option's dosage, route, safety, and contraindications are evaluated, focusing on the latest research and clinical studies. In conclusion, this review highlights the need for individualized treatment plans considering the underlying hormonal imbalances and associated factors contributing to male infertility.

1. Introduction

Infertility is characterized as the inability to attain pregnancy after one year of engaging in unprotected sexual intercourse [1]. Meanwhile, it is common for couples not using contraceptive measures to conceive within 12 months, with 80 to 85% of them successfully achieving pregnancy [2]. However, approximately 15% of couples may experience challenges in conceiving [3]. Male infertility, in some instances, can be attributed to anatomical abnormalities, including varicoceles, ductal obstructions, or ejaculatory disorders [4]. A multicenter study carried out by the World Health Organization (WHO), the primary causes of infertility were identified as male factors in 20% of cases, female factors in 38% cases, 27% to abnormalities in both partners and 15% were unexplained factors [5,6]. Male factor infertility was specifically associated with various semen anomalies such as sperm morphology, count and motility [7,8].

According to medical sources, infertility is referred as the failure of a couple to conceive a pregnancy despite a year of consistent and unprotected sexual intercourse [9,10]. It has been found that half of all cases of infertility are caused by male infertility [11]. Which can result from congenital or acquired conditions that impact the hypothalamic-pituitary-testicular (HPT) axis [12-14]. Although ongoing research is examining the underlying causes, approximately 40% of cases remain idiopathic, and genetic factors could play a role as contributing factors [15].

1.1 Causes of male infertility

A typical semen sample is anticipated to exhibit a quantity of 1.5 to 5ml, containing a sperm concentration exceeding 20 million/ml [16-19], whereby less than 40% of the sperm demonstrate abnormal morphology, and more than 30% of the sperm adequately mobile [7,20]. According to Tripathi et al., (2023) that male infertility, responsible for 40% to 90% cases, may arise to inadequate sperm production of unknown etiology [21]. Male infertility may be due to azoospermia or oligozoospermia (lack of or inadequate sperm), tetratozoospermia (abnormal sperm morphology), and asthenozoospermia (asthenospermia) (decrease sperm motility) [22], which may hinder the impregnation of female partners [23-25]. Table 1. shows the causes, diagnosis, and treatments of male infertility.

Causes of Male Infertility	Description	Diagnostics	Treatments	Lifestyle Changes	Risk Factors	Associated Conditions	References
Chromosomal abnormalities	Defects or missing chromosomes, such as Klinefelter syndrome or Y-chromosome microdeletions	Karyotyping, genetic testing	Testicular sperm extraction, donor sperm, adoption	Genetic counseling, healthy diet, exercise	Family history, age, exposure to toxins, radiation, chemotherapy	Cystic fibrosis, developmental delays, learning disabilities	26,27
Varicocele	Enlarged veins in the scrotum that can cause low sperm count and motility	Physical exam, ultrasound	Varicocelectomy and assisted reproductive techniques	Avoid tight clothing, moderate exercise	Age, obesity, smoking, alcohol, sedentary lifestyle	Testicular atrophy, pain, swelling, reduced testosterone level	28,29
Infections	Inflammatory or infectious diseases, such as epididymitis, prostatitis, or sexually transmitted infections	Physical exam, semen analysis, cultures	Antibiotics, antivirals, surgery	Practice safe sex, good hygiene	History of sexually transmitted infections, multiple sexual partners, poor hygiene	Chronic pelvic pain, urinary symptoms, prostatitis	30,31
Endocrine disorders	Hormonal imbalances, such as hypogonadism or hyperprolactinemia	Hormone testing	Hormone replacement therapy, assisted reproductive techniques	Healthy diet, exercise, stress reduction	Obesity, type 2 diabetes, thyroid dysfunction, pituitary tumors	Erectile dysfunction, decreased libido, gynecomastia	32-34
Medications and drugs	Certain medications or recreational drugs, such as anabolic steroids, chemotherapy, or marijuana	Medical history, drug testing	Discontinuation of medicine, drug rehabilitation	Avoid smoking, moderate alcohol intake	Use of anabolic steroids, chemotherapy, opioids, marijuana	Reduced sperm count and motility, abnormal sperm morphology, erectile dysfunction	35,36

Idiopathic infertility	Infertility without an identifiable cause	Comprehensive evaluation	Assisted reproductive techniques, adoption	Healthy lifestyle, stress reduction	Age, stress, environmental factors, exposure to toxins	Unknown	37,38
Obstructive azoospermia	Obstruction or absence of the vas deferens or ejaculatory ducts	Semen analysis, ultrasound, genetic testing	Surgical reconstruction, assisted reproductive techniques	Avoid exposure to toxins, moderate exercise	Congenital abnormalities, infection, injury, inflammation	Cystic fibrosis, Young syndrome, Kartagener syndrome	39,40
Non-obstructive azoospermia	Failure to produce or ejaculate sperm	Semen analysis, hormone testing, testicular biopsy	Assisted reproductive techniques, donor sperm, adoption	Healthy diet, exercise, stress reduction	Age, exposure to toxins, radiation, chemotherapy, genetic factors	Klinefelter syndrome, Y-chromosome microdeletions, testicular cancer, cryptorchidism	41-43

Table .1 Causes, diagnosis and related treatments of male infertility

Several scientific studies have reported that male infertility is frequently caused by anomalies in spermatozoa, such as insufficient quantities (azoospermia/oligospermia), poor motility, and abnormal structure/morphology [44]. The quality and quantity of spermatozoa have reduced in recent decades, which has led to a growing male factor contribution to the escalating prevalence of infertility worldwide [7,44]. The WHO has acknowledged a decrease in sperm count and has a consequently revised the diagnostic standards for normal and abnormal sperm counts that are employed in andrology laboratories worldwide [45]. Unfortunately, primary treatment methods for male infertility showed limited effectiveness, with only a minor proportion of male factor infertility being amenable to resolution through such measures [44,46]. However, male factor infertility can be mitigated by employing secondary measures including artificial insemination, intra-uterine insemination, in vitro fertilization and embryo transfer, intra-cytoplasmic sperm transfer, and child fostering/adoption [47]. Nevertheless, there is a paucity of data on the primary causes and risk factors that contribute to the rising of male infertility [48]. A comprehensive understanding of these causes and risk factors is essential to devise primary prevention strategies and efficacious treatment modalities for male infertility. This understanding also facilitates the development of innovative secondary and tertiary interventions to address this issue [49,50].

Numerous causes and risk factors associated with male infertility have been identified and documented in the scientific literature, including smoking, alcohol intake, drug use, obesity, testicular infections (past or present), exposure to environmental toxins, excessive heat exposure of the testicles, hormonal disorders, testicular trauma, and ejaculatory/erectile disorders [51,52]. Currently, there exists a scarcity of comprehensive studies that consolidate and prioritize potential causative agents and risk factors contributing to male infertility, in order to establish a consensus on the causal chain and identify simple preventive and therapeutic approaches. Although the factors involved in male infertility have been generally delineated, distinguishing patterns of causation and risk will facilitate further investigation and advancements in pinpointing the precise mechanisms and pathways underlying the observed decline in male reproductive capacity [53].

1.2 Importance of hormonal balance in male fertility

Hormonal balance is crucial for male fertility which is regulated by a complex interplay of hormones, including follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, and prolactin [54,55]. These hormones control the production, maturation, and health of sperm, as well as maintaining the proper functioning of the reproductive organs [55,56]. An imbalance in these hormones can negatively impact male fertility by causing reduced sperm count, decreased sperm motility, and abnormal sperm morphology [57]. In severe cases, this can result in complete infertility [57]. Additionally, hormonal imbalances can lead to other health problems, such as erectile dysfunction, low libido, and gynecomastia (enlarged breasts in men) [58].

Some of the common hormonal disorders that can affect male fertility include hypogonadism (low testosterone levels), hyperthyroidism (overactive thyroid gland), and hypothyroidism (underactive thyroid gland) [59,60]. Meanwhile, various factors, including genetic predisposition, medications, and lifestyle choices can cause these disorders [61,62]. Moreover, men need to maintain a healthy hormonal balance to ensure optimal reproductive function. This can be achieved through lifestyle changes such as regular exercise, healthy and nutritious diet, stress management, and avoiding exposure to environmental toxins [63]. Treatment options for hormonal imbalances include hormone replacement therapy, medication, and lifestyle changes [64].

In summary, hormonal balance plays a crucial role in male fertility. Any imbalance in the hormones that regulate the male reproductive system can lead to a range of reproductive and other health problems. Maintaining a healthy hormonal balance through lifestyle changes and appropriate treatment can help to improve male fertility and overall health.

Moreover, the hypothalamic-pituitary-gonadal (HPG) axis is responsible for regulating male reproductive hormone levels. This complex system involves three key components: the hypothalamus, pituitary gland, and testes [65]. By maintaining the appropriate concentration of hormones, the axis supports male sexual development and function. However, any disruption to the system can result in infertility [65]. For instance, if the brain fails to produce gonadotropic releasing hormone (GnRH), this can cause a lack of testosterone and a cessation of sperm production [66]. This type of disorder is known as hypogonadotropic hypogonadism, and it encompasses a range of conditions stemming from GnRH deficiency [66].

Gonadotropin-releasing hormone deficiency can lead to various conditions, including Kallmann syndrome. Changes in sense of smell and immaturity characterize this disorder [67]. To treat gonadotropin-releasing hormone deficiency, healthcare providers may recommend various options such as the use of sex steroids, gonadotropins, and injections of gonadotropin-releasing hormone [68]. In particular, testosterone injections are often prescribed to help to restore normal testosterone levels, and stimulate the development of secondary sexual characteristics [69].

Suppose the pituitary gland fails to produce adequate levels of LH and FSH. In that case, the testes may not be properly stimulated, resulting in reduced production of testosterone and sperm [70]. Patients with pituitary deficiency may require long-term hormone therapy, which can be associated with complications such as Diabetes Mellitus (DM), Cardiovascular diseases (CVD), and bone defects [71]. Conversely, high concentrations of LH and FSH are sometimes associated with low testosterone levels and testicular failure (Hypergonadotropic hypogonadism), which also associated with defects in spermatogenesis [71]. Additionally, elevated prolactin levels can contribute to reduced sperm production, decreased libido, and impotence [72]. Hyperprolactinemia can cause infertility in up to 11% of people with oligospermia [73]. However, in many cases, treatment with a dopamine agonist can be an effective approach [73]. After roling out any pitutary adenoma with imaging.



2. Hormonal Dysfunction and Male Infertility

Hormonal dysfunction is a common cause of male infertility. Hormones are responsible for regulating many functions in the male reproductive system, including the production of sperm [74]. Hormonal imbalances can disrupt this delicate balance, leading to a decrease in sperm count or quality, and ultimately, infertility [74]. One of the most common hormonal disorders that can lead to male infertility is hypogonadism [75]. Which is a condition where the testes do not produce enough testosterone, the primary male sex hormone [75]. Testosterone is essential for the production of sperm, so a deficiency in this hormone can resulted in low sperm count and poor sperm quality [76]. Other hormonal disorders that can cause male infertility include hyperprolactinemia, a condition where the pituitary gland produces too much prolactin, and thyroid disorders, which can disrupt the balance of hormones in the body [77].

Treatment for hormonal dysfunction and male infertility varies depending on the underlying cause. In some cases, medications may be used to correct hormonal imbalances, while in other cases, surgery may be necessary to address an underlying condition [74].

2.1 Role of Hormones in male fertility

Follicle-stimulating hormone is a hormone produced by the pituitary gland in the brain, and it plays a crucial role in male fertility [78]. In men, FSH stimulates the development and maturation of the seminiferous tubules in the testes, which are responsible for the production of sperm [78]. Furthermore, FSH also acts on the Sertoli cells in the testes, which provide nourishment and support to developing sperm cells and stimulates the Sertoli cells to produce and secrete various proteins and hormones that are necessary for the maturation of sperm cells [79].

Fig. 1 Role of Hormones in male fertility

Moreover, LH is produced by the brain pituitary gland, and it plays an essential role in male fertility [80]. In men, LH stimulates the Leydig cells in the testes to produce testosterone, which is necessary for the development of sperm and other male reproductive tissues [80]. Testosterone regulates the production of sperm, libido, and erectile function. LH levels can be used as a marker of testicular function and can help diagnose conditions such as hypogonadism and infertility. Insufficient levels of LH can precipitate a reduction in testosterone production. Conversely, elevated levels of LH may suggest a state of primary testicular failure, where the testes are ineffectual in producing testosterone in response to LH stimulation. In females, LH levels are pivotal for the regulation of the menstrual cycle, while in males, it is primarily involved in the regulation of testosterone production and male fertility. Figure. 1 shows the role of hormones in male fertility.

3. Current Diagnostic Techniques for Hormonal Dysfunction in Male Infertility

Blood tests are a current diagnostic technique used to evaluate hormonal dysfunction in male infertility [81]. These could be used to measure hormone levels, including testosterone, FSH, LH, and estradiol [82]. Abnormal hormone levels might indicate a hormonal imbalance that could contribute to male infertility [83]. Blood tests are a non-invasive and relatively simple diagnostic tool that may help healthcare professionals to determine the cause of hormonal dysfunction and develop an appropriate treatment plan [83].

3.1 Blood tests

Hormonal imbalances affect males reproductive system, and blood tests are used to identify these imbalances [84]. Elevated FSH levels indicate non-obstructive infertility, while low testosterone levels may lead to erectile dysfunction and low sex drive. Blood tests could also help to identify underlying conditions that may contribute to hormonal imbalances, such as hypothyroidism or hyperthyroidism [85]. Moreover, blood tests could be used to monitor the effectiveness of hormonal replacement therapy (HRT) or gonadotropin therapy in treating male infertility. Overall, blood tests play an important role in the diagnosing and managing male infertility.

A blood test is used to measure the testosterone level, which may help diagnose conditions such as hypogonadism which affect male fertility [86]. Recently, a study investigated the diagnostic value of multiple hormonal markers, including testosterone, FSH, LH, and inhibin B to diagnose male infertility [87]. The study found that low testosterone levels (< 300 ng/dL) were observed in 15.9% of infertile men, while elevated FSH levels (> 10 mIU/mL) were observed in 21.5% of infertile men. In addition, low inhibin B levels (< 80 pg/mL) were observed in 26.5% of infertile men [88]. Previously, it was also evaluated that multiple hormonal markers improved the diagnostic accuracy for identifying male infertility. Specifically, the combination of low testosterone, elevated FSH, and low inhibin B had a sensitivity of 75% and specificity of 87% in diagnosing male infertility [89].

A blood test that measures FSH level may also be used to detect diseases that may impact male fertility, such as primary testicular failure (high FSH levels) [87]. Previously, it was observed that FSH levels in the blood could be used as a diagnostic tool for male infertility. The study found that men with FSH levels above 11.4 mIU/mL had a significantly higher risk of infertility, with a sensitivity of 77% and a specificity of 75% [90]. Similarly, the study found that FSH levels were negatively correlated with sperm count, motility, and morphology, indicating that high FSH levels may be associated with impaired spermatogenesis [91].

Luteinizing hormone (LH) stimulates the production of testosterone from the testes. It is measured by blood tests, which help to diagnose conditions such as primary testicular failure (high FSH levels) [92]. Similarly, men with hypogonadotropic hypogonadism had lower LH and FSH levels than fertile men, with a sensitivity of 89.7% and a specificity of 93.8% [93]. Previous results concluded that measuring LH levels in the blood is a useful diagnostic tool for identifying these conditions that may contribute to male infertility [94].

Prior research has indicated a correlation between elevated levels of prolactin and thyroid-stimulating hormone (TSH) in the blood with male infertility. The relationship between serum prolactin levels and semen parameters in men with infertility was evaluated previously [95]. Ahmad et al. (2017) found that men with higher levels of prolactin had lower sperm concentrations, lower sperm motility, and a higher percentage of abnormal sperm compared to men with normal prolactin levels. Furthermore, the association between TSH levels and semen parameters in infertile men was also studied [96]. It was suggested that men with higher TSH levels had lower sperm concentrations and lower sperm motility compared to men with normal TSH levels [96].

It is important to note that both prolactin and TSH levels may provide important information about male infertility, they are not the only factors to be considered, and the interpretation of hormone levels should be made in conjunction with additional laboratory and clinical observations.

4. Current Treatment Option for Hormonal Dysfunction in Male Infertility

4.1 Hormonal replacement therapy

Hormonal replacement therapy (HRT) is a medical treatment that supplements or replaces naturally occurring hormones in the body with synthetic hormones. It is commonly used to treat symptoms associated with hormonal imbalances or deficiencies, such as menopause or hypogonadism [97]. HRT may involve replacing or supplementing estrogen, progesterone, or testosterone hormones. The type and dosage of hormones used in HRT may depend on the specific condition being treated, the patient's health status, and other factors. HRT may be administered through a various methods, including pills, injections [97]. Table. 2 shows different hormones used in hormonal replacement therapy.

Hormone	Indication	Administration Route	Dosage	Monitoring	Adverse Effects	Contraindications	References
FSH and LH	Hypogonadotropic Hypogonadism	Subcutaneous injection	Individualized based on serum levels and clinical response	Serum testosterone and estradiol levels, semen analysis	Testicular enlargement, breast tenderness, mood changes	Hypersensitivity to gonadotropins, primary testicular failure, obstructive azoospermia	98
Clomiphene	Hypogonadism, Subfertility	Oral tablets	25-50mg/day for 3-6 months	Serum testosterone and estradiol levels, semen analysis	Hot flashes, mood changes, visual disturbances, gynecomastia	History of thromboembolic events, liver disease, pituitary tumor	98
Aromatase Inhibitors	Hypogonadism, Androgen Deficiency	Oral tablets	Individualized based on serum levels and clinical response	Serum testosterone, estradiol, and lipid levels	Hot flashes, mood changes, joint pain, decreased bone mineral density	Osteoporosis, liver disease, history of thromboembolic events	98

Table. 2 Different hormones in Hormonal replacement therapy

4.1.1 Selective estrogen receptor modulators (SERMs)

Selective estrogen receptor modulators (SERM) administration significantly increased sperm concentration, total sperm count, and serum LH, FSH, and total testosterone levels [99]. SERMs like clomiphene, tamoxifen, and enclomiphene citrate are used in males for various problems related to hormonal imbalances [100]. Clomiphene citrate is commonly used to treat male infertility due to low testosterone levels. It may work by blocking estrogen receptors in the hypothalamus and pituitary gland, which may stimulate LH and FSH production. These hormones then stimulate the testes to produce more testosterone and increase sperm production , which may improve fertility [101]. Previously, clomiphene citrate was also studied as a treatment for male infertility. The results of 11 randomized controlled trials (RCTs) found that clomiphene citrate improved sperm concentration, motility, and morphology in men with idiopathic oligozoospermia [102]. In another systematic review and meta-analysis, during clomiphene citrate treatment, TS, FSH, LH, and estradiol levels increased. There were no significant side effects seen throughout the follow-up period. Pregnancy rates were recorded in ten investigations, with a mean of 17% with clomiphene citrate medication (0%-40%) [103]. Similarly, tamoxifen and enclomiphene citrate may also be used to treat male infertility, although they are less commonly prescribed for this purpose. They work in a similar way to clomiphene citrate by blocking estrogen receptors and stimulating the production of LH and FSH [104]. A randomized, double-blind, placebo-controlled study of 70 men with idiopathic oligozoospermia found that tamoxifen citrate treatment significantly improved sperm concentration, motility, and morphology compared to placebo [105].

Overall, using SERMs such as clomiphene, tamoxifene, and enclomiphene citrate has shown promise as a treatment option for men with hypogonadism, male infertility, and other conditions related to hormonal imbalances. However, further research is needed to understand their efficacy and potential side effects.

4.1.2 Aromatase inhibitors

Aromatase inhibitors (AIs) such as anastrozole, testolactone, and letrozole may be used as hormone therapy in males. AIs in males are used to treat gynecomastia caused by an imbalance of hormones, precisely an excess of estrogen relative to testosterone [106]. AIs work by blocking the conversion of testosterone to estrogen, which may reduce the amount of estrogen in the body and help to shrink breast tissue [107]. In men with hypogonadism, testosterone replacement therapy (TRT) may increase testosterone levels but it also increase estrogen levels due to the conversion of testosterone to estrogen. AIs may be combined with TRT to block the conversion of testosterone to estrogen and maintain a more balanced hormonal environment [107]. Previously, a systematic review and meta-analysis of 17 RCTs concluded that AIs effectively improve sperm concentration and motility in men with non-obstructive azoospermia and oligozoospermia [108]. Moreover, testolactone had also been shown to be effective in treating gynecomastia, with a study of 28 men showing a significant reduction in breast size and tenderness [109].

4.1.3 Gonadotropin therapy

Gonadotropin therapy in males is a medical treatment that involves the use of hormones to help stimulate the production of testosterone by the testes [104]. The therapy is typically used to treat a condition called hypogonadism, which is characterized by low levels of testosterone in the body [104]. In the case of hypogonadism, the problem may lie in the hypothalamus or pituitary gland, which are responsible for producing the hormones that regulate testosterone production [110]. Gonadotropin therapy may help bypass these organs and directly stimulate the Leydig cells in the testes to produce testosterone [111]. The most common type of gonadotropin therapy used in males is human chorionic gonadotropin (hCG) therapy, also known as hCG stimulation. Moreover, hCG is a hormone that is structurally similar to LH, which normally stimulates testosterone production in the testes [112].

However, hCG therapy typically involves a series of injections of hCG over several weeks or months. The injections are usually given intramuscularly, and the dosage and frequency of injections will depend on the individual's specific needs and response to treatment [113]. Moreover, hCG therapy may be combined with other forms of testosterone replacement therapy, such as testosterone injections or gels [114]. Treatment for male infertility often involves 6-12 months of hCG therapy to stimulate testosterone secretion before adding FSH [115]. In some cases, hCG alone may lead to the spontaneous appearance of sperm duration ejaculation.

The combination of hCG and hMG therapy has successfully induced spermatogenesis in 40% to 75% of cases, as evidenced by a positive sperm count [116]. However, it is difficult to assess the actual rate of success and noncompliance due to the retrospective nature of many studies. Patients who discontinue treatment at early stages are unlikely to be included in such studies, which primarily report on long-term outcomes such as the initiation of spermatogenesis and pregnancy [114].

5. Limitations and Side Effects of Hormonal Therapy for Male Infertility

Hormonal therapy treats male infertility due to hormonal dysfunction but it has limitations and potential side effects. It may not work for all cases and may be expensive. It is not a lifelong treatment and may need to be discontinued due to side effects or other concerns. Side effects may include acne, breast enlargement, mood changes, decreased fertility, and an increased risk of health problems [117]. It is important to discuss potential risks and benefits with a healthcare professional before starting treatment and monitor for side effects during therapy.

5.1 Potential side effects of gonadotropin therapy

Gonadotropin therapy stimulates the production of FSH and LH, which regulate the production of testosterone and sperm in the testes. While gonadotropin therapy may be effective in treating male infertility, it also has potential side effects that should be considered [118]. Some of the common side effects of gonadotropin therapy include the following [119]:

1. Gonadotropin therapy may affect mood and cause irritability, anxiety, or depression. These mood changes may have a negative impact on daily life and may require further treatments.
2. In certain males, it has the potential to induce breast tissue growth, resulting in breast enlargement or tenderness. This condition is known as gynecomastia and may be uncomfortable or embarrassing for some men.
3. It may cause acne or worsen existing acne that may be bothersome for some men, especially if they are prone to acne or have sensitive skin.
4. It may cause testicular pain or swelling in some men, which becomes uncomfortable.
5. It is quite possible that the risk of multiple births increases due to assisted reproductive technologies such as in vitro fertilization. Multiple pregnancies may increase the risk of complications for both the mother and the babies.
6. Some people may have allergic reactions such as itching, hives, or difficulty in breathing.

6. Conclusion

Infertility in men may significantly impact a couple's social and psychological well-being. Addressing the issues and improving the patient's reproductive health is essential. Male infertility may cause from various factors, including social, genetic, and environmental factors.

Meanwhile, HRT is successfully used to treat male infertility HRT is administered through injections or tablets . The treatment works by increasing pituitary hormonal prodcutin speficically FSH and LH which will result in increase testosterone levels in the body, improve sperm production and fertility. HRT is also recommended for men with low testosterone levels due to hypogonadism or pituitary gland disorders. It may be used to treat men who have low testosterone levels due to aging or certain medications.

However, HRT is inappropriate for all men with hormonal imbalances and male infertility. Men who have certain medical conditions such as prostate cancer, breast cancer, or blood clots may not be able to receive HRT. Furthermore, HRT may have side effects such as acne, breast enlargement, and mood changes.

A healthcare professional should evaluate the case to determine if HRT is a suitable treatment option. Other treatment options, such as clomiphene citrate, human chorionic gonadotropin, or gonadotropin-releasing hormone agonists and antagonists, may be recommended instead or in addition to HRT.

Personalized treatment plans are essential in healthcare, especially treating complex ailments such as hormonal dysfunction in male infertility. Every individual has a different case, and treatment plans must be tailored to their needs.

Various factors are contributed to hormonal dysfunction in male infertility, including age, medical history, lifestyle habits, and genetics. Therefore, a complete evaluation and diagnosis by a healthcare professional are necessary to determine the underlying cause of the hormonal dysfunction and to develop an appropriate treatment method.

Personalized treatment plans consider the individual's unique situation, preferences, and goals, as some individuals may prefer a non-invasive treatment approach, while others may be more willing to undergo surgery. Moreover, some individuals may have comorbidities to consider when acquiring a treatment method. However, a personalized treatment plan may lead to better outcomes and higher patient satisfaction. When individuals are actively involved in their treatment plan, they are more likely to follow the recommended treatments and make necessary lifestyle changes.

Overall, personalized treatment plans are essential in healthcare, particularly for complex conditions such as hormonal dysfunction in male infertility.

Future research and clinical practice related to hormonal dysfunction and male infertility could focus on several areas.

1. There is a need to investigate new treatment options that are more effective and targeted.
2. Identifying biomarkers could help accurately diagnose hormonal dysfunction and predict treatment outcomes.
3. Addressing lifestyle factors such as diet, exercise, and stress could improve hormonal balance and fertility.
4. Improving diagnosis through more sensitive and specific diagnostic tests could lead to more effective treatment.
5. Research could examine the long-term impacts of treatment regarding fertility outcomes.

Clinical practices could involve individualized treatment methods considering the patient's specific needs and goals, education on lifestyle interventions that may improve fertility, and collaboration with fertility specialists and other healthcare professionals to develop comprehensive treatment plans.

7. funding:

This review Self-funded. No fund received from any organization.

8. References

1. Henkel R, Offor U, Fisher D. The role of infections and leukocytes in male infertility. *Andrologia*. 2021;53(1):e13743.
2. Sirait BI, Reviani N, Udjung GI. Factors Affecting Infertility in Women of Reproductive Age in the IVF Programme. *International Journal of TROPICAL DISEASE & Health*. 2023;44(1):65-75.
3. Belladelli F, Muncey W, Seranio N, Eisenberg ML. Counseling for the man with severe male infertility. *Current Opinion in Urology*. 2023;33(1):5-9.
4. ÇAYAN S. Surgical Treatment of Male Infertility. *Duzce Medical Journal*. 2022;24(Special Issue):30-35.
5. Krausz C, Forti G. Clinical aspects of male infertility. *The genetic basis of male infertility*. 2000:1-21.
6. Viswambharan N, Manavalan M. Sperm abnormalities: in the male partners of infertile couples from Kanyakumari District. *International Journal of Infertility & Fetal Medicine*. 2021;11(1):16-19.
7. Bannison Bani S, Anachem R, Banyeh M, et al. Study on Semen Quality among Men Seeking Infertility Treatment in Tamale, Ghana. *Asian Journal of Research and Reports in Urology*. 2023;6(1):27-36.
8. Ling X, Cui H, Chen Q, et al. Sperm telomere length is associated with sperm nuclear DNA integrity and mitochondrial DNA abnormalities among healthy male college students in Chongqing, China. *Human Reproduction*. 2023:dead065.
9. Yang T, Wongpakaran N, Wongpakaran T, et al. Factors Associated with Anxiety and Depression in Infertile Couples—Study Protocol. Healthcare: MDPI; 2022. p. 1352.
10. Nazar I, Tariq A, Tanvir F, Raza F. Prevalence of Infertility in Young Women, a Survey Based Study from Punjab, Pakistan. *International Journal of Medical Science and Clinical Invention*. 2023;10(01):6538-6542.
11. Aprea I, Wilken A, Krallmann C, et al. Pathogenic gene variants in CCDC39, CCDC40, RSPH1, RSPH9, HYDIN, and SPEF2 cause defects of sperm flagella composition and male infertility. *Frontiers in Genetics*. 2023;14.

12. Akram M, Handelsman DJ, Qayyum M, et al. Genetic analysis of failed male puberty using whole exome sequencing. *Journal of Pediatric Endocrinology and Metabolism*. 2022;35(11):1410-1421.
13. Kopa Z, St. Laurent F, Szücs N. Male Hypogonadism. *Andrology and Sexual Medicine*. Springer; 2022:289-304.
14. Al-Sharefi A, Quinton R. Current national and international guidelines for the management of male hypogonadism: helping clinicians to navigate variation in diagnostic criteria and treatment recommendations. *Endocrinology and Metabolism*. 2020;35(3):526-540.
15. Sen ES, Ramanan A. Juvenile idiopathic arthritis-associated uveitis. *Clinical Immunology*. 2020;211:108322.
16. Majed AH, Rasheed MK, Jasim MO. Seminal fluid analysis changes after testicular varicocelectomy in a sample of Iraqi patients. 2020.
17. Villani MT, Morini D, Spaggiari G, et al. Are sperm parameters able to predict the success of assisted reproductive technology? A retrospective analysis of over 22,000 assisted reproductive technology cycles. *Andrology*. 2022;10(2):310-321.
18. Yland JJ, Eisenberg ML, Hatch EE, et al. A North American prospective study of depression, psychotropic medication use, and semen quality. *Fertility and Sterility*. 2021;116(3):833-842.
19. Manikandan I, Bora S, Adole PS, Thyagaraju C, Ganesh RN. Assessment of organophosphate pesticides exposure in men with idiopathic abnormal semen analysis: a cross-sectional pilot study. *International Journal of Fertility & Sterility*. 2021;15(3):219.
20. Nassir M, Levi M, Shaked NT. Dynamic 3D Modeling for Human Sperm Motility through the Female Cervical Canal and Uterine Cavity to Predict Sperm Chance of Reaching the Oocyte. *Cells*. 2023;12(1):203.
21. Tripathi AK, Ray AK, Mishra SK, Bishen SM, Mishra H, Khurana A. Molecular and Therapeutic Insights of Alpha-Lipoic Acid as a Potential Molecule for Disease Prevention. *Revista Brasileira de Farmacognosia*. 2023:1-16.
22. Krausz C, Farnetani G. Clinical Interpretation of Semen Analysis. *Practical Clinical Andrology*. Springer; 2022:173-184.
23. Sedova AO, Shtaut MI, Bragina EE, et al. Comprehensive semen examination in patients with pancreatic-sufficient and pancreatic-insufficient cystic fibrosis. *Asian Journal of Andrology*. 2023:10.4103.
24. Janiszewska E, Kokot I, Kmieciak A, Gilowska I, Faundez R, Kratz EM. Are There Associations between Seminal Plasma Advanced Oxidation Protein Products and Selected Redox-Associated Biochemical Parameters in Infertile Male Patients? A Preliminary Report. *Cells*. 2022;11(22):3667.
25. Sharma A, Minhas S, Dhillo WS, Jayasena CN. Male infertility due to testicular disorders. *The Journal of Clinical Endocrinology & Metabolism*. 2021;106(2):e442-e459.
26. Krausz C, Rosta V, Swerdloff RS, Wang C. Genetics of male infertility. *Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics*. Elsevier; 2022:121-147.
27. Ioannou D, Tempest HG. Meiotic nondisjunction: insights into the origin and significance of aneuploidy in human spermatozoa. *The male role in pregnancy loss and embryo implantation failure*. 2015:1-21.

28. Cannarella R, Calogero AE, Condorelli RA, Giacone F, Aversa A, La Vignera S. Management and treatment of varicocele in children and adolescents: an endocrinologic perspective. *Journal of Clinical Medicine*. 2019;8(9):1410.
29. Malasevskaia I, Al-Awadhi AA, Raza FA. Fertility outcomes after varicocele repair: are there any benefits? A traditional review. *Fortune Journal of Health Sciences*. 2021;4(2):284-298.
30. Narvekar S. Microbiology of Semen and Male Genital Tract Infections. *Principles & Practice of Assisted Reproductive Technology (3 Vols)*. 2013;1:200.
31. Gimenes F, Souza RP, Bento JC, et al. Male infertility: a public health issue caused by sexually transmitted pathogens. *Nature Reviews Urology*. 2014;11(12):672-687.
32. Petak SM, Nankin HR, Spark RF, et al. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update. *Endocrine Practice*. 2002;8(6):439-456.
33. Faron-Górecka A, Latocha K, Pabian P, Kolasa M, Sobczyk-Krupiarz I, Dziedzicka-Wasylewska M. The Involvement of Prolactin in Stress-Related Disorders. *International Journal of Environmental Research and Public Health*. 2023;20(4):3257.
34. Zavaleta MC, Ibarra JLP, Ramos-Yataco A, et al. Assessment of hormonal status in male infertility. An update. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2022:102447.
35. Fang C, Wang F, Shen Y, Yu X, Chang D, Ye Y. The roles and potential mechanisms of Traditional Chinese Medicine on male infertility. *Pharmacological Research-Modern Chinese Medicine*. 2022:100129.
36. Chehab M, Madala A, Trussell J. On-label and off-label drugs used in the treatment of male infertility. *Fertility and sterility*. 2015;103(3):595-604.
37. Bracke A, Peeters K, Punjabi U, Hoogewijs D, Dewilde S. A search for molecular mechanisms underlying male idiopathic infertility. *Reproductive biomedicine online*. 2018;36(3):327-339.
38. Santi D, Spaggiari G, Granata AR, Simoni M. Real World Evidence analysis of the FSH use in male idiopathic infertility. *Best practice & research Clinical obstetrics & gynaecology*. 2022.
39. Wan B, Wu Y, Wu Z, Zhou Z, Lu W. Current progress on the curative effects of vasoepididymostomy for patients with obstructive azoospermia: An updated systematic review and meta-analysis of human studies. *Andrology*. 2023;11(1):103-111.
40. Abdelaal NE, Tanga BM, Abdelgawad M, et al. Cellular therapy via spermatogonial stem cells for treating impaired spermatogenesis, non-obstructive azoospermia. *Cells*. 2021;10(7):1779.
41. Wu X, Lin D, Sun F, Cheng CY. Male infertility in humans: an update on non-obstructive azoospermia (NOA) and obstructive azoospermia (OA). *Molecular Mechanisms in Spermatogenesis*. 2021:161-173.
42. Kasak L, Laan M. Monogenic causes of non-obstructive azoospermia: challenges, established knowledge, limitations and perspectives. *Human genetics*. 2021;140(1):135-154.
43. Han F, Jiang X, Li Z-m, et al. Epigenetic inactivation of SOX30 is associated with male infertility and offers a therapy target for non-obstructive azoospermia. *Molecular Therapy-Nucleic Acids*. 2020;19:72-83.

44. Okonofua FE, Ntoimo LFC, Omonkhua A, et al. Causes and risk factors for Male infertility: A scoping review of published studies. *International Journal of General Medicine*. 2022:5985-5997.
45. Esteves SC. Evolution of the World Health Organization semen analysis manual: where are we? *Nature Reviews Urology*. 2022;19(7):439-446.
46. Rabie AM. COVID-19 and sexual dysfunction in men: SARS-CoV-2 in the testes. *Sexologies*. 2021;30(4):e141-e148.
47. Soliman BS, Harira M. Local endometrial scratching under ultrasound-guidance after failed intrauterine insemination and cycle outcome: A randomized controlled trial. *Middle East Fertility Society Journal*. 2017;22(1):60-66.
48. Wasilewski-Masker K, Seidel K, Leisenring W, et al. Male infertility in long-term survivors of pediatric cancer: a report from the childhood cancer survivor study. *Journal of Cancer Survivorship*. 2014;8:437-447.
49. Schlegel PN, Sigman M, Collura B, et al. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I. *The Journal of urology*. 2021;205(1):36-43.
50. Biggs SN, Kennedy J, Lewis SL, et al. Lifestyle and environmental risk factors for unexplained male infertility: study protocol for Australian Male Infertility Exposure (AMIE), a case–control study. *Reproductive Health*. 2023;20(1):1-9.
51. Cargnelutti F, Di Nisio A, Pallotti F, et al. Risk factors on testicular function in adolescents. *Journal of Endocrinological Investigation*. 2022;45(9):1625-1639.
52. Kasman AM, Del Giudice F, Eisenberg ML. New insights to guide patient care: the bidirectional relationship between male infertility and male health. *Fertility and Sterility*. 2020;113(3):469-477.
53. Lavranos G, Balla M, Tzortzopoulou A, Syriou V, Angelopoulou R. Investigating ROS sources in male infertility: a common end for numerous pathways. *Reproductive Toxicology*. 2012;34(3):298-307.
54. Sengupta P, Dutta S. Hormones in male reproduction and fertility. *Asian Pac J Reprod*. 2019;8(5):187-188.
55. Sofikitis N, Giotitsas N, Tsounapi P, Baltogiannis D, Giannakis D, Pardalidis N. Hormonal regulation of spermatogenesis and spermiogenesis. *The Journal of steroid biochemistry and molecular biology*. 2008;109(3-5):323-330.
56. Thackray VG, Mellon PL, Coss D. Hormones in synergy: regulation of the pituitary gonadotropin genes. *Molecular and cellular endocrinology*. 2010;314(2):192-203.
57. Cannarella R, Gül M, Rambhatla A, Agarwal A. Temporal decline of sperm concentration: Role of endocrine disruptors. *Endocrine*. 2023;79(1):1-16.
58. Maseroli E, Rastrelli G, Corona G, et al. Gynecomastia in subjects with sexual dysfunction. *Journal of Endocrinological Investigation*. 2014;37:525-532.
59. Dittrich R, Beckmann MW, Oppelt PG, et al. Thyroid hormone receptors and reproduction. *Journal of reproductive immunology*. 2011;90(1):58-66.
60. Krassas GE, Markou KB. The impact of thyroid diseases starting from birth on reproductive function. *Hormones*. 2019;18(4):365-381.
61. Durairajanayagam D. Lifestyle causes of male infertility. *Arab journal of urology*. 2018;16(1):10-20.
62. Bisht S, Faiq M, Tolahunase M, Dada R. Oxidative stress and male infertility. *Nature Reviews Urology*. 2017;14(8):470-485.

63. Areta JL, Taylor HL, Koehler K. Low energy availability: history, definition and evidence of its endocrine, metabolic and physiological effects in prospective studies in females and males. *European Journal of Applied Physiology*. 2021;121(1):1-21.
64. Reis L, Favaro W, Barreiro G, et al. Erectile dysfunction and hormonal imbalance in morbidly obese male is reversed after gastric bypass surgery: a prospective randomized controlled trial. *International Journal of Andrology*. 2010;33(5):736-744.
65. Matuszewska A, Kowalski K, Jawień P, et al. The Hypothalamic-Pituitary-Gonadal Axis in Men with Schizophrenia. *International Journal of Molecular Sciences*. 2023;24(7):6492.
66. Keskin T, Erden Y, Tekin S. Intracerebroventricular asprosin administration strongly stimulates hypothalamic-pituitary-testicular axis in rats. *Molecular and cellular endocrinology*. 2021;538:111451.
67. Cariboni A, André V, Chauvet S, et al. Dysfunctional SEMA3E signaling underlies gonadotropin-releasing hormone neuron deficiency in Kallmann syndrome. *The Journal of clinical investigation*. 2015;125(6):2413-2428.
68. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. *The Journal of Clinical Endocrinology & Metabolism*. 2017;102(11):3869-3903.
69. Salonia A, Rastrelli G, Hackett G, et al. Paediatric and adult-onset male hypogonadism. *Nature reviews Disease primers*. 2019;5(1):38.
70. Corradi PF, Corradi RB, Greene LW. Physiology of the hypothalamic pituitary gonadal axis in the male. *Urologic Clinics*. 2016;43(2):151-162.
71. Kim SY. Diagnosis and treatment of hypopituitarism. *Endocrinology and Metabolism*. 2015;30(4):443-455.
72. Cookson J, Hodgson R, Wildgust HJ. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. *Journal of Psychopharmacology*. 2012;26(5_suppl):42-51.
73. Badar A, Khilwani B, Lohiya NK, Ansari AS. Etiology of male infertility: a review. *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*.11(8):2321.
74. Darbandi M, Darbandi S, Agarwal A, et al. Reactive oxygen species and male reproductive hormones. *Reproductive Biology and Endocrinology*. 2018;16(1):1-14.
75. Yeap BB, Wu FC. Clinical practice update on testosterone therapy for male hypogonadism: contrasting perspectives to optimize care. *Clinical Endocrinology*. 2019;90(1):56-65.
76. Fallah A, Mohammad-Hasani A, Colagar AH. Zinc is an essential element for male fertility: a review of Zn roles in men's health, germination, sperm quality, and fertilization. *Journal of reproduction & infertility*. 2018;19(2):69.
77. Maggi M, Buvat J, Corona G, Guay A, Torres LO. Hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA). *The journal of sexual medicine*. 2013;10(3):661-677.
78. An K, Yao B, Tan Y, Kang Y, Su J. Potential Role of Anti-Müllerian Hormone in Regulating Seasonal Reproduction in Animals: The Example of Males. *International Journal of Molecular Sciences*. 2023;24(6):5874.
79. Lu T, Mortimer M, Li F, et al. Putative adverse outcome pathways of the male reproductive toxicity derived from toxicological studies of perfluoroalkyl acids. *Science of The Total Environment*. 2023:162439.

80. Hasan AF, Hassan BF, AL-SAMERAIE AY. Correlation of Insulin Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein with LH, FSH and Testosterone in Iraqi Children with Growth Hormone Deficiency. *Iraqi Journal of Chemical and Petroleum Engineering*. 2023;24(1):89-95.
81. Becatti M, Cito G, Argento FR, et al. Blood Leukocyte ROS Production Reflects Seminal Fluid Oxidative Stress and Spermatozoa Dysfunction in Idiopathic Infertile Men. *Antioxidants*. 2023;12(2):479.
82. Goss DM, Vasilescu SA, Sacks G, Gardner DK, Warkiani ME. Microfluidics facilitating the use of small extracellular vesicles in innovative approaches to male infertility. *Nature Reviews Urology*. 2023;20(2):66-95.
83. Nunes DC, Ribeiro JC, Alves MG, Oliveira PF, Bernardino RL. Male Sex Hormones, Metabolic Syndrome, and Aquaporins: A Triad of Players in Male (in) Fertility. *International Journal of Molecular Sciences*. 2023;24(3):1960.
84. Ogo FM, Siervo GEML, Praxedes AM, et al. Gestational exposure to continuous light impairs the development of the female reproductive system in adult Wistar rat offspring. *Birth Defects Research*. 2023.
85. Akset M, Poppe KG, Kleynen P, Bold I, Bruyneel M. Endocrine disorders in obstructive sleep apnoea syndrome: A bidirectional relationship. *Clinical Endocrinology*. 2023;98(1):3-13.
86. Li M, Yang L, Liu S, Chen L, Ma CC. Endocrine Late Effects of Radiation Therapy in Pediatric and Young Adult Patients with Brain Tumors. *Mathews Journal of Cancer Science*. 2023;8(1):1-27.
87. Tao Y. Endocrine aberrations of human nonobstructive azoospermia. *Asian Journal of Andrology*. 2022;24(3):274.
88. Li Y, Hu L, Zhou B, et al. The association between organophosphate esters exposure and body mass index in children and adolescents: The mediating effect of sex hormones. *Chemosphere*. 2023;324:138305.
89. Liu J, Huang J, Gao L, et al. Maternal exposure to PM2. 5 disrupting offspring spermatogenesis through induced sertoli cells apoptosis via inhibin B hypermethylation in mice. *Ecotoxicology and Environmental Safety*. 2022;241:113760.
90. Medicine PCotASfR. Testing and interpreting measures of ovarian reserve: a committee opinion. *Fertility and sterility*. 2015;103(3):e9-e17.
91. Ramcharn M, Hampshire T, Tatarov O, et al. The Value of Serum Follicle-Stimulating Hormone in Predicting Successful Surgical Sperm Retrieval in Cases of Male Infertility: A Literature Review. *Reproductive Health*. 2022:39.
92. Yücel C, Keskin MZ, Kose C, Kucuk U, Ilbey YO, Kozacioğlu Z. Relationship between testicular histopathology and the success of testicular sperm extraction in patients with non-mosaic Klinefelter syndrome. *Revista internacional de andrologia*. 2021;19(1):9-15.
93. Xie Y, Yao J, Zhang X, et al. A panel of extracellular vesicle long noncoding RNAs in seminal plasma for predicting testicular spermatozoa in nonobstructive azoospermia patients. *Human Reproduction*. 2020;35(11):2413-2427.
94. Ozkocer SE, Konac E. The current perspective on genetic and epigenetic factors in sperm maturation in the epididymis. *Andrologia*. 2021;53(3):e13989.
95. Ahmed ND, Ahmed HS. The relationships between serum prolactin level and semen analysis parameters among patients attended the reproductive health center, Khartoum 2016–2017. *Sudan Medical Monitor*. 2017;12(2):41.

96. Chaudhuri GR, Das A, Kesh SB, et al. Obesity and male infertility: multifaceted reproductive disruption. *Middle East Fertility Society Journal*. 2022;27(1):8.
97. Hormones B. A comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risks. *Altern Med Rev*. 2006;11(3):208-223.
98. Krzastek SC, Smith RP. Non-testosterone management of male hypogonadism: an examination of the existing literature. *Translational Andrology and Urology*. 2020;9(Suppl 2):S160.
99. Cannarella R, Condorelli RA, Mongioì LM, Barbagallo F, Calogero AE, La Vignera S. Effects of the selective estrogen receptor modulators for the treatment of male infertility: a systematic review and meta-analysis. *Expert opinion on pharmacotherapy*. Aug 2019;20(12):1517-1525. https://doi.org10.1080/14656566.2019.1615057.
100. Rambhatla A, Mills JN, Rajfer J. The role of estrogen modulators in male hypogonadism and infertility. *Reviews in urology*. 2016;18(2):66.
101. Patel AS, Leong JY, Ramos L, Ramasamy R. Testosterone is a contraceptive and should not be used in men who desire fertility. *The world journal of men's health*. 2019;37(1):45-54.
102. Li J, Wu Q, Ng EHY, Mol BWJ, Wu XK, Wang CC. Effects of Medicines and Supplements on Spontaneous Pregnancy and Semen Parameters in Male Infertility: A Systematic Review Update and Network Meta-Analysis. *Engineering*. 2022;16:198-209.
103. Huijben M, Huijsmans RLN, Lock MTWT, de Kemp VF, de Kort LMO, van Breda JHMK. Clomiphene citrate for male infertility: A systematic review and meta-analysis. Andrology;n/a(n/a). https://doi.orghttps://doi.org/10.1111/andr.13388.
104. Desai A, Yassin M, Cayetano A, Tharakan T, Jayasena CN, Minhas S. Understanding and managing the suppression of spermatogenesis caused by testosterone replacement therapy (TRT) and anabolic–androgenic steroids (AAS). *Therapeutic Advances in Urology*. 2022;14:17562872221105017.
105. Lucignani G, Jannello LMI, Fulgheri I, et al. Coenzyme Q10 and Melatonin for the Treatment of Male Infertility: A Narrative Review. *Nutrients*. 2022;14(21):4585.
106. Yang C, Li P, Li Z. Clinical application of aromatase inhibitors to treat male infertility. *Human Reproduction Update*. 2022;28(1):30-50.
107. Guo B, Li Jj, Ma Yl, Zhao Yt, Liu Jg. Efficacy and safety of letrozole or anastrozole in the treatment of male infertility with low testosterone-estradiol ratio: a meta-analysis and systematic review. *Andrology*. 2022;10(5):894-909.
108. Garg H, Kumar R. Empirical drug therapy for idiopathic male infertility: what is the new evidence? *Urology*. 2015;86(6):1065-1075.
109. Soliman AT, De Sanctis V, Yassin M. Management of adolescent gynecomastia: an update. *Acta Bio Medica: Atenei Parmensis*. 2017;88(2):204.
110. Errico A, Vinco S, Ambrosini G, et al. Mitochondrial Dynamics as Potential Modulators of Hormonal Therapy Effectiveness in Males. *Biology*. 2023;12(4):547.
111. Khodamoradi K, Khosravizadeh Z, Seetharam D, Mallepalli S, Farber N, Arora H. The role of leptin and low testosterone in obesity. *International journal of impotence research*. 2022:1-10.
112. Bakhtyukov AA, Derkach KV, Sorokoumov VN, et al. The effects of separate and combined treatment of male rats with type 2 diabetes with metformin and orthosteric and allosteric agonists of luteinizing hormone receptor on steroidogenesis and spermatogenesis. *International Journal of Molecular Sciences*. 2022;23(1):198.

113. Fink J, Schoenfeld BJ, Hackney AC, Maekawa T, Horie S. Human chorionic gonadotropin treatment: a viable option for management of secondary hypogonadism and male infertility. *Expert Review of Endocrinology & Metabolism*. 2021;16(1):1-8.
114. Jayasena CN, Anderson RA, Llahana S, et al. Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. *Clinical endocrinology*. 2022;96(2):200-219.
115. Tatem AJ, Beilan J, Kovac JR, Lipshultz LI. Management of anabolic steroid-induced infertility: novel strategies for fertility maintenance and recovery. *The World Journal of Men's Health*. 2020;38(2):141.
116. Esteves SC, Achermann AP, Simoni M, Santi D, Casarini L. Male infertility and gonadotropin treatment: what can we learn from Real World Data? *Best Practice & Research Clinical Obstetrics & Gynaecology*. 2022:102310.
117. Ko EY, Siddiqi K, Brannigan RE, Sabanegh Jr ES. Empirical medical therapy for idiopathic male infertility: a survey of the American Urological Association. *The Journal of urology*. 2012;187(3):973-978.
118. Laursen RJ, Alsbjerg B, Elbaek HO, et al. Recombinant gonadotropin therapy to improve spermatogenesis in nonobstructive azoospermic patients–A proof of concept study. *International braz j urol*. 2022;48:471-481.
119. Oh J-w, Yun Y, Lee ES. A Review of Gender-Affirming Hormone Therapy for Transgender and Gender Diverse Adults in South Korea. *Journal of Menopausal Medicine*. 2022;28(3):92-102.